Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | GABRE | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5201244 | 0.85 | KDM4E (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6995112 | 0.84 | KDM4E (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3890064 | 0.83 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3890211 | 0.83 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3891895 | 0.82 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6604123 | 0.81 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6499506 | 0.81 | GABRP (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3887759 | 0.78 | GABRP (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3889498 | 0.77 | PARP1 (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3887674 | 0.76 | CYP3A4 (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495018-B2 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1268474-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074811-A2 | SUBSTITUTED 1,3-THIAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | GABRP 2014/4885GABRD 3060/4885GABRA1 3503/4885 |
| US-20040053973-A1 | Substituted 1,3-thiazole compounds, their production and use | MAPK1, MAP4K2, MAPK4 | GABRP 2877/4885GABRD 3707/4885GABRA1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.